cancer
Conditions
Interventions
[18F]FMISO Dose: 320-400 MBq Injected quantity: 5 mL (Maximum) Administration method: Single intravenous dose [18F]DiFA Dose: 600-740 MBq Injected quantity: 3 mL (Maximum) Administration meth
Sponsors
Hokkaido University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients diagnosed with cancer in a doctor's visit to Hokkaido University Hospital or in Hokkaido University Hospital stay. Satisfy the following conditions; (1)aged 20-70 years old at agreement acquisition. (2)gave a written informed consent. (3)diagnosed with cancer with clinical manifestation, clinical course, imaging, and histo-pathological examination. (4)confirmed the lesion in CT, MRI or FDG-PET.
Exclusion criteria
Exclusion criteria: (1) Pregnant women, breast-feeding women, or women who may be pregnant. (2)with hepatic or renal disease. (3) Karnofsky performance status(KPS) under 40. (4) an acute disease symptom (nausea, vomiting, fever, diarrhea) within 3 days before administering. (5) a history of hypersensitivity for medical drugs. (6) a participation in other clinical trials at present or within 6 months (180 days) before consent. (7) diagnosed by [18F]DiFA-PET within 90 days before consent. (8) a history of drug abuse or alcoholism. (9) considered as inappropriate for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare [18F]DiFA accumulation with [18F]FMISO accumulation to hypoxia region in tumor. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)To clarify the presence or the absence, the type, the severity, and frequency of adverse effects and to assess the shift of laboratory test values by the administration of [18F]DiFA. 2)To estimate the optimum amount of radioactivity and imaging time of [18F]DiFA PET for cancer patient. | — |
Countries
Japan
Contacts
Public ContactTohru Shiga
Hokkaido University, Graduate School of Medicine N15, W7, Kita-Ku, Sapporo
Outcome results
None listed